Omnimmune Holdings, Inc. (OMMH) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Houston, United States. The current CEO is Howard Becker.
OMMH has IPO date of 2022-12-30, 2 full-time employees, listed on the Other OTC, a market capitalization of $981.00.
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
